NACLC23

Friday,
December 1
17:30 - 19:30
Industry Supported Symposia Sponsored by Regeneron

Location:

Chicago Ballroom ABCD

ISS-01: A Compelling Case-Based Discussion Examining Actual Patients with Advanced NSCLC

This is a 60-min presentation aiming to examine personalized medicine in advanced NSCLC. The presentation will outline clinical evidence and important safety data for Libtayo, review a patient case study with advanced NSCLC and explore how to initiate treatment with Libtayo in appropriate patients. The program is sponsored and content developed by Regeneron Pharmaceuticals, Inc.

Presenter: Frank Weinberg, MD, PhD

Saturday, December 2
12:00 - 13:00
Industry Supported Symposia Sponsored by Merck

Location:
Chicago Ballroom E

ISS-02: A Treatment Option for Certain Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

Learning Objectives

Review and understand the disease state and the role of the multidisciplinary team
Understand how patient characteristics may influence your treatment plan
Review approved indication and clinical data supporting a treatment option for patients with resectable NSCLC

Presenter: Ammar Sukari, MD

Saturday, December 2
19:00 - 20:30
Industry Supported Symposia Sponsored by Eli Lilly

Location:
Chicago Ballroom E

ISS-03: Shattering the Status Quo: A First-Line Precision Therapy for mNSCLC

Join us to learn about Phase III head-to-head data for this targeted agent in NSCLC. During the presentation, we will discuss the prevalence of RET fusions, explore the importance of testing for actionable biomarkers before beginning treatment, examine the unmet need for patients with RET-altered NSCLC, and review clinical trial data including comparison to standard of care, safety, and warnings and considerations for dose modifications in eligible patients.

Chair: Tarek Mekhail, MD